Form 4 Tracker
Syndax Pharmaceuticals Inc
SNDX

14 insider filings · Latest: Jun 11, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Jun 12, 2026Jun 12 9:09 PMNicholas A.J. BotwoodHead of R&D, CMO
Sale
31,235$18.14$566.6K60,885(D)

View →

Jun 11, 2026Jun 12 9:09 PMNicholas A.J. BotwoodHead of R&D, CMO
Sale
34,280$18.00$617.0K60,885(D)

View →

Jun 12, 2026Jun 12 8:10 PMBotwood Nicholas A.J.
Proposed Sale
31,235$18.14$566.7K

View →

Jun 11, 2026Jun 11 8:12 PMBotwood Nicholas A.J.
Proposed Sale
34,280$17.78$609.4K

View →

Jun 1, 2026Jun 2 8:30 PMKeith A. GoldanChief Financial Officer
Sale
1,177$18.99$22.4K139,252(D)

View →

Jun 1, 2026Jun 2 8:30 PMMichael A MetzgerDirector, Chief Executive Officer
Sale
6,847$18.99$130.0K484,843(D)

View →

Jun 1, 2026Jun 1 7:59 PMGoldan Keith A.
Proposed Sale
1,177$18.99$22.4K

View →

Jun 1, 2026Jun 1 7:54 PMMetzger Michael A
Proposed Sale
6,847$18.99$130.0K

View →

Feb 9, 2026Feb 10 2:00 PMMichael A MetzgerDirector, Chief Executive Officer
Sale
17,159$21.03$360.8K491,690(D)

View →

Feb 9, 2026Feb 10 1:59 PMKeith A. GoldanChief Financial Officer
Sale
3,410$21.03$71.7K140,429(D)

View →

Feb 9, 2026Feb 9 8:57 PMMetzger Michael A
Proposed Sale
17,159$21.03$360.8K

View →

Feb 9, 2026Feb 9 8:42 PMGoldan Keith A.
Proposed Sale
3,410$21.03$71.7K

View →

Feb 6, 2026Feb 6 10:54 PMMichael A MetzgerDirector, Chief Executive Officer
Sale
7,412$20.62$152.8K508,849(D)

View →

Feb 6, 2026Feb 6 10:53 PMKeith A. GoldanChief Financial Officer
Sale
2,082$20.62$42.9K143,839(D)

View →

Feb 6, 2026Feb 6 8:47 PMMetzger Michael A
Proposed Sale
7,412$20.62$152.8K

View →

Feb 6, 2026Feb 6 8:43 PMGoldan Keith A.
Proposed Sale
2,082$20.62$42.9K

View →

Sep 8, 2025Sep 8 8:25 PMMICHAEL METZGER
Proposed Sale
157,307$17.04$2.7M

View →

Aug 18, 2025Aug 18 8:36 PMDENNIS G PODLESAK
Proposed Sale
14,400$15.74$226.7K

View →

Aug 14, 2025Aug 14 8:26 PMDENNIS G PODLESAK
Proposed Sale
43,200$13.45$581.0K

View →

Jul 16, 2025Jul 16 7:29 PMGoldan Keith A.
Proposed Sale
1,296$9.29$12.0K

View →

Page 1 of 2

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 12, 2026Jun 12 9:09 PMNicholas A.J. BotwoodHead of R&D, CMO
Option Exercise
31,235$13.820(D)

View →

Jun 11, 2026Jun 12 9:09 PMNicholas A.J. BotwoodHead of R&D, CMO
Option Exercise
22,515$13.820(D)

View →

Feb 4, 2026Feb 6 10:54 PMMichael A MetzgerDirector, Chief Executive Officer
Grant/Award
440,000$20.43440,000(D)

View →

Feb 4, 2026Feb 6 10:53 PMKeith A. GoldanChief Financial Officer
Grant/Award
118,000$20.43118,000(D)

View →

Feb 4, 2026Feb 6 9:50 PMNicholas A.J. BotwoodHead of R&D, CMO
Grant/Award
144,700$20.43144,700(D)

View →